Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. (RUBY): 4 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.5 months
D/E 0.52 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Rubius Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.9M
Quarterly Burn
$32.5M
Runway
1.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Rubius Therapeutics, Inc.'s pipeline?
Rubius Therapeutics, Inc. (RUBY) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rubius Therapeutics, Inc.'s lead drug candidate?
Rubius Therapeutics, Inc.'s most advanced tracked candidate is rtx-224 (Phase 2) for Relapsed/refractory or locally advanced solid tumors (including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer).
What is Rubius Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rubius Therapeutics, Inc. has approximately 1.5 months of cash runway.
Who is the CEO of Rubius Therapeutics, Inc.?
Abigail P. Johnson is the chief executive officer of Rubius Therapeutics, Inc. (RUBY).
Get the full picture on Rubius Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.